25 years of live related renal transplantation in children: The Buenos Aires experience
The number of pediatric patients with end stage renal disease (ESRD) has been steadily growing during the last 10 years all over the world, because of the improvement of medical and surgical treatment of severe urologic malformations and congenital and acquired nephrological disorders. Kidney transp...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2007-01-01
|
Series: | Indian Journal of Urology |
Subjects: | |
Online Access: | http://www.indianjurol.com/article.asp?issn=0970-1591;year=2007;volume=23;issue=4;spage=443;epage=451;aulast=Ruiz |
Summary: | The number of pediatric patients with end stage renal disease (ESRD) has been steadily growing during the last 10 years all over the world, because of the improvement of medical and surgical treatment of severe urologic malformations and congenital and acquired nephrological disorders. Kidney transplantation (Tx) with a live related donor continues to be the gold standard therapy to treat ESRD in children because of the best final results, the chronic lack of cadaveric donors and the frequent possibility of young patients to have parents or relatives as a source of a potential graft donor.
Nowadays almost every pediatric patient can be dialyzed and transplanted, even early in life, if he or she has the possibility of a live related donor. Improvements in pediatric anesthesiology and intensive care have also been very important, in reducing the morbidity and mortality related to Tx procedures.
Here we report our experience with Tx for the last 25 years, specially our long experience of live related donor transplantation in children and adolescents with emphasis on technical issues in small children and pediatric patients with severe urologic malformations and bladder dysfunction. We′ll make special considerations on the improvement in short and long follow-up with the actual prevention and treatment of graft rejection, due to the new immunosuppressive agents and protocols. |
---|---|
ISSN: | 0970-1591 1998-3824 |